OncoMatch/Clinical Trials/NCT02143830
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Is NCT02143830 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for fanconi anemia.
Treatment: Busulfan · Cyclophosphamide · Fludarabine · rabbit ATG · G-CSF · Peripheral blood stem cell — The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or matched unrelated donors following a preparative regimen of busulfan, fludarabine, anti-thymocyte globulin and cyclophosphamide.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Lab requirements
Kidney function
serum creatinine <1.5 mg/dl or if serum creatinine is outside the normal range, then crcl > 50 ml/min/1.73 m2
Liver function
< 5 x upper limit of normal (uln) alanine transaminase (alt) and < 2.0 mg/dl total serum bilirubin
Cardiac function
asymptomatic or if symptomatic then 1) left ventricular ejection fraction (lvef) at rest must be > 50% and must improve with exercise or 2) shortening fraction > 29%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
- Cincinnati Children's Hospital Medical Center · Cincinnati, Ohio
- Fred Hutchinson Cancer Research Center · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify